Helping India
Apr. 26th, 2021 06:34 pmIn short: A key issue when it comes to vaccine equity is intellectual property protections. Over 100 countries support a proposed temporary waiver of intellectual property rights - a WTO TRIPS waiver - related to COVID vaccines. This waiver would allow vaccines to be manufactured generically worldwide, leading to a significant increase in vaccine production. The vast majority of the development costs of the COVID-19 vaccines were paid for through public funds, making it especially perverse to insist on patent enforcement. As Professors Madhavi Sunder and Matthew Kavanagh of Georgetown University observe: "These technologies, paid for by taxes, should be treated as public goods—compensating innovators fairly, but not with a global monopoly over producing and pricing vaccines critical to saving lives and ending the pandemic." (Bloomberg Law)
For US, UK, and EU residents: